Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin

NCT00024323 is registered in ClinicalTrials.gov with Vion Pharmaceuticals as lead sponsor.

NCT NCT00024323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin
Lead sponsor
Vion Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2001
Completion date
June 30, 2003
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unspecified adult solid tumor, protocol specific